Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research
Michael J. Burke(Children's Hospital of Wisconsin), Carrie L. Kitko(Vanderbilt University Medical Center), Michael A. Pulsipher(Primary Children's Hospital), Michael R. Verneris(NHS Blood and Transplant), R. Maarten Egeler(Leiden University Medical Center), Robert J. Hayashi(Washington University in St. Louis), Jennifer Le Rademacher(Medical College of Wisconsin), Niketa C. Shah, Haydar Frangoul(Children’s Hospital at TriStar Centennial), Kimberly A. Kasow(University of North Carolina at Chapel Hill), Nirali N. Shah(National Institutes of Health), Lamis Eldjerou, Christopher C. Dvorak(University of California, San Francisco), Allistair Abraham(Children's National), Elizabeth Thiel(Medical College of Wisconsin), Wing Leung(KK Women's and Children's Hospital), Hisham Abdel‐Azim(University of Southern California), Richard F. Olsson(AstraZeneca (Netherlands)), Wensheng He(Medical College of Wisconsin), Gregory M.T. Guilcher(University of Calgary), Mouhab Ayas(King Faisal Specialist Hospital & Research Centre), Valerie I. Brown(BC Children's Hospital), Jeffery J. Auletta(Nationwide Children's Hospital), Julie‐An Talano(Dana-Farber Cancer Institute), Miguel Ángel Díaz(Hospital Infantil Universitario Niño Jesús), Ahmed Ibrahim, Ka Wah Chan(Methodist Children’s Hospital), Mitchell S. Cairo(New York Medical College)
Cited by 37
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k